Apurinic/apyrimidinic endonuclease 1 (APE1) is an essential protein crucial for repair of oxidized DNA damage not only in genomic DNA but also in mitochondrial DNA. Parkin, a tumor suppressor and Parkinson's disease (PD) associated gene, is an E3 ubiquitin ligase crucial for mitophagy. Although DNA damage is known to induce mitochondrial stress, Parkin's role in regulating DNA repair proteins has not been elucidated. In this study, we examined the possibility of Parkindependent ubiquitination of APE1. Ectopically expressed APE1 was degraded by Parkin and PINK1 via polyubiquitination in mouse embryonic fibroblast cells. PD-causing mutations in Parkin and PINK1 abrogated APE1 ubiquitination. Interaction of APE1 with Parkin was observed by co-immunoprecipitation, proximity ligation assay, and co-localization in the cytoplasm. N-terminal deletion of 41 amino acid residues in APE1 significantly reduced the Parkin-dependent APE1 degradation. These results suggested that Parkin directly ubiquitinated N-terminal Lys residues in APE1 in the cytoplasm. Modulation of Parkin and PINK1 activities under mitochondrial or oxidative stress caused moderate but statistically significant decrease of endogenous APE1 in human cell lines including SH-SY5Y, HEK293, and A549 cells. Analyses of glioblastoma tissues showed an inverse relation between the expression levels of APE1 and Parkin. These results suggest that degradation of endogenous APE1 by Parkin occur when cells are stressed to activate Parkin, and imply a role of Parkin in maintaining the quality of APE1, and loss of Parkin may contribute to elevated APE1 levels in glioblastoma.
INTRODUCTION
Oxidatively damaged DNA is primarily repaired by DNA base excision repair. In the mammalian DNA base excision repair pathway, apurinic/apyrimidinic (AP) endonuclease (APE1) incises DNA upstream of AP sites to generate single-strand breaks (SSBs) with 3 0 -OH termini for subsequent DNA repair synthesis reactions [1] . APE1 is shown to be essential during mouse embryonic development and is the only active AP-endonuclease in mammals. Studies also demonstrated that APE1 was indispensable for cultured cells [2, 3] , although recent studies demonstrated that cells derived from a B lymphocyte line could survive without APE1 [4, 5] . APE1 also functions as a gene expression regulator by redoxically activating oncogenic and pro-survival transcription factors such as AP-1 and NF-kB, and is also involved in gene regulation necessary for calcium homeostasis [6, 7] . Therefore, APE1 is a pro-survival multifunctional protein. Drug and radiation resistance of tumor tissues have been linked to increased APE1 expression [8] [9] [10] [11] [12] .
APE1 is post-translationally modified by phosphorylation, acetylation, and ubiquitination [13] [14] [15] [16] [17] [18] [19] . APE1 was found to be ubiquitinated by MDM2 [20, 21] , the major p53 regulator [22, 23] .
However, APE1 ubiquitination was later observed in mouse embryonic fibroblast defective of MDM2 [20] , implying existence of backup activities for APE1 ubiquitination other than MDM2. Meisenberg et al. identified UBR3 as another E3 ubiquitin ligase for APE1 [24] .
Properly maintained mitochondrial membrane potential is critical to meet cellular energy demands through oxidative phosphorylation. Electron leaks from the respiratory chain complexes result in the generation of superoxide (O À 2 ). The mitochondrial superoxide dismutase is extremely efficient in scavenging O À 2 [25] , and thus cells at normal growth conditions maintain the oxidative stress at a manageable level. This status quo may be broken by exogenous reagents, genotoxic stresses, and gene mutations that impair mitochondria [26] [27] [28] . Damaged mitochondria elevate intracellular reactive oxygen species (ROS), and result in further impairment of mitochondria [29] . To avoid this vicious cycle, a salvaging process named mitophagy is initiated to break down damaged mitochondria and generate new mitochondria [30] . It is becoming apparent that mitophagy is modulated by DNA damage responses. Recent studies found that activation of poly(ADP-ribose) polymerase 1 (PARP1) by DNA strand breaks plays a pivotal role in the energy metabolism [31, 32] . In the process of DNA repair, oxidative DNA damage is converted to DNA strand breaks as intermediate lesions [33] . The suppression of mitophagy by the activated PARP may be a selffeedback system during the repair of endogenous DNA damage. However, understanding the interplay among factors for mitophagy and DNA repair proteins is far from complete.
During mitophagy, proteins in damaged mitochondria are degraded via polyubiquitination, which is mainly carried out by Parkin, a RING domain-containing E3 ubiquitin ligase [34] . PINK1 (PTEN-inducedkinase 1) is a critical activator of Parkin [30, 34] . PINK1 phosphorylates ubiquitin and Parkin [35] [36] [37] [38] , and recruits Parkin from cytoplasm to mitochondrial surfaces to facilitate ubiquitination of its target proteins such as mitofusin 2 (Mfn2), Miro, and VDAC1 [39, 40] . Mutations in the Parkin and the PINK1 genes cause mitochondrial degeneration and are associated with PD [30] and glioblastoma (GBM) [41, 42] .
Considering that Parkin expression is induced by p53 [43, 44] which enhances APE1 ubiquitination [21] , it is possible that Parkin ubiquitinates APE1. Moreover, a recent proteomics study for identifying Parkin's substrates and interacting proteins revealed APE1 as one of possible targets of Parkin [45] . These observations prompted us to investigate the activity of Parkin for APE1 ubiquitination. In this study, we investigated functional and physical interactions between APE1, Parkin, and PINK1.
MATERIALS AND METHODS

DNA, Cell Culture, and Transient Transfection
All cDNAs in plasmid expression vectors used in this study are of humans. Expression vectors for YFPParkin (23955) and cMyc-PINK1 (13314) [46, 47] were obtained from Addgene. Non-tagged wild-type (wt) PINK1 was then cloned by PCR amplification into pcDNA3.1 (Invitrogen, Waltham, MA). The fulllength human Parkin and its specific E2 ligase UbcH7 were cloned for this study by PCR cloning from quick cDNA clone (Clontech, Mountain View, CA) using Phusion Taq DNA polymerase (NEB) with appropriate primers synthesized (Integrated DNA Technology, Coralville, IW) into the pcDNA3.1Zeo-(þ) expression vector (Invitrogen). Mutations (R275W and C431F in Parkin and G309D in PINK1) were introduced by PCR subcloning. The pBi16, a mammalian expression vector with a flippase recognition target (FRT) site and a doxycycline (dox) inducible-dual promoter [48] , is a generous gift from Dr. Grabczyk. The human Parkin and PINK1 cDNAs were cloned into pBi16 (named pBi16-PaPi, Supplemental Figure S1 ) for inducing both proteins together with dox. All sequences of DNA amplified by PCR were confirmed by DNA sequencing (ACGT Inc., Wheeling, IL and GenScript Inc., Piscataway, NJ). MEF la , a mouse embryonic fibroblast cells, deficient in mouse Ape1 (mApe1) and expressing hAPE1 was described previously for its extremely low APE1 expression [49] . The MEF la cells were cultured in DMEM High Glucose medium (Hyclone, Logan, UT) supplemented with 10% fetal bovine serum (Gemini Inc., West Sacramento, CA), 1% penicillin/streptomycin, 1% L-glutamine (Hyclone). SH-SY5Y (a human neuroblastoma) and A549 (a human lung adenocarcinoma) were purchased from ATCC. The HEK293 derivative T-Rex 293 was purchased from Invitrogen. The T-Rex 293 cells were transfected with pBi16-PaPi and pOG44 expressing flippase (Flp). 293/pBI16-PaPi (293-PaPi) stable transfectants were selected with 150 mg/mL hygromycin. The 293-PaPi cells were plated on 60 mm dishes (1 Â 10 6 /dish). After overnight incubation, Parkin and PINK1 were induced with 2 mg/mL dox. At the same time, drugs indicated in the results were added in the culture medium, and together incubated for 16 h. Cells were then harvested for immunoblot analyses.
For transient transfection, cells were plated on 60 mm dishes with cell numbers between 4 Â 10 5 and 1 Â 10 6 and incubated for overnight. Lipofectamine 2000 (Invitrogen) was used for transfection using OptiMEM-I (Invitrogen) with the vendors' manual. PINK1 siRNA was purchased from Applied Biosystem, Waltham, MA. Introduction of siRNA was standardized for minimum cytotoxicity as the following method. Semi-confluent SH-SY5Y cells were suspended in the DMEM medium at 1 Â 10 7 cells/mL, and mixed with 200 nM siRNA. Cell/siRNA suspensions in 0.1 cm cuvettes were then electroporated using ECM 830 square wave electroporation system (BTX) at 920 V, 120 mF, 2 pulses at 0.1 s interval. After 15 min at room temperature, cells were transferred to 100 mm dishes (Corning) containing DMEM complete media, and incubated for 72 h. When necessary, 10 mM carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was added after 48 h, and further incubated for 24 h (total 72 h after the electroporation). Cells were then harvested and examined with immunoblot.
Immunoblot (Western Blot) Assay
Whole cell extracts were prepared from cells detached by scraping after being washed with PBS twice, and resuspended in RIPA buffer [50] supplemented with proteinase inhibitor cocktail (Roche Life Science, Indianapolis, IN) and 40 mM MG132. After adjusting protein concentration, the extracts were run in 10% acrylamide SDS-PAGE, transferred to PVDF membrane (Bio-Rad, Hercules, CA), and blotted with appropriate antibodies. SDS-PAGE samples were run with a pre-stained protein size marker (NEB, P7709).
Detection of Ubiquitinated APE1 in A549
Histidine hexamer-tagged ubiquitin (6xHis-ub) cDNA was transfected with APE1, Parkin, and PINK1 in A549 cells and incubated for 24 h. The cells were lysed in the binding buffer (20 mM Tris pH 8.0, 0.5 M NaCl, 0.1 % NP-40, 10 mM imidazole) with 40 mM MG132 (Sigma, St. Louis, MO) and proteinase inhibitor cocktail without EDTA (Roche). The crude cell extracts (total fraction) were incubated with Ni-NTA magnetic beads (Qiagen) for 15 min at 48C, washed with the binding buffer, and eluted with binding buffer with 120 mM imidazole. The total and eluted (His-tagged protein-enriched) fractions were analyzed by immunoblot using anti-APE1 antibody.
Analysis of Localization of YFP-Parkin and APE1
MEF la cells were spread on coverslips a day before DNA transfection. The cDNA carrying YFP-Parkin and APE1 were co-transfected in the same way as described above, and incubated for 24 h. If necessary, MG132 was added and incubated. Cells were incubated in the presence of Mitotracker Red (Invitrogen), fixed in 3.7% formaldehyde, and then permeabilized in PBS containing 0.2% Triton X-100 for 15 min. After washing with PBS twice, cells were blotted with anti-APE1 antibody, stained with anti-mouse IgG antibody conjugated to Alexa Fluor 488 (Invitrogen) followed by DAPI staining, and mounted on glass plates with Vector Lab mounting reagent. Cells were then analyzed with Leica TSP SP5 Confocal Microscope confocal microscopy at the Imaging Core facility of University of Kentucky.
Co-Immunoprecipitation (Co-IP) of Recombinant APE1-FLAG and Parkin Escherichia coli BLR(DE3) strain (EMB Biosciences, Waltham, MA) was transformed with a pRSF-Duet1 derivative (EMD) carrying Parkin and either of APE1-FLAG or APE1 (negative control) cDNAs. The cells were grown until OD600 reached 0.6-0.8, and then expressions of the proteins were induced with 0.5 mM IPTG (Fisher) at 168C for 16 h [20, 51] . Cells were lysed in a co-IP buffer (120 mM NaCl, 2 mM EDTA, 0.1 mM EGTA, 0.05% NP40, 1 mM DTT, 50 mM HEPES, pH 7.9) supplemented with proteinase inhibitor cocktail (Complete Ultra Mini, Roche). After centrifugation for 20 min at 48C, small portions of supernatants were kept separately as total fractions (inputs), and the remaining samples were subjected to immunoprecipitation with agarose resin conjugated to the anti-FLAG antibody M2 (Sigma). The resin was washed in the co-IP buffer, and eluted in 100 mg/mL FLAG peptide (Sigma), and both total and IP fractions were analyzed by immunoblotting using anti-APE1 and anti-Parkin antibodies.
Proximity Ligation Assay (PLA)
A549 cells were spread on coverslips and incubated for overnight before transfection of the APE1 and Parkin cDNA. The cells were then incubated with 1 mM Mitotracker RED for 1 h, and fixed in 100% methanol at À208C and then in 100% ice-cold acetone.
The samples were processed according to the OLINK Bioscience DuoLink In Situ protocol. Briefly, the coverslips were rehydrated in PBS (pH7.5) containing 0.1% Triton X-100 (v/v) for at least 30 min at room temperature. The samples were then blocked with 5% BSA in PBSþ Triton X-100 for 30 min. The primary antibodies were applied (1:200 ms-anti-parkin, 1:250 rb-anti-APE1) and incubated overnight at 48C in a humidity chamber; all other incubations were carried out in a 378C humidity chamber unless otherwise noted. The samples were washed and incubated with the Duolink secondary antibodies (anti-mouse and anti-rabbit IgG) for 1 h. After washing, the samples were incubated with the ligation reaction mixture for 30 min, washed, and then further incubated with the green amplification reagent for 90 min. After the final wash, the samples were mounted with Duolink In Situ mounting medium containing DAPI. The fluorescent signals in the cells were analyzed using an Olympus inverted fluorescence microscope.
Tissue Extract Preparation
Snap-frozen GBM specimens were obtained from male patients (50-75 yr old) in accordance with IRB regulations. Whole cell lysates of the tissues were prepared using the Fisher Cryo-homogenizing system. Briefly, the samples were disaggregated through grinding with a clean pre-chilled mortar and pestle. The samples were then transferred to a microcentrifuge tube and RIPA buffer, containing 40 mM MG132 and protease inhibitors, was added to an approximate concentration of 10 mg/mL pre-ground weight. The samples were then centrifuged to collect large debris, and the supernatant was used to prepare a stock in SDS-PAGE loading buffer and to determine final protein concentration. The SDS-PAGE stock was sonicated and incubated at 708 C for 5 min and stored at À808 C until use. Before SDS-PAGE, the samples were diluted to a final concentration of 3 mg/mL in SDS-PAGE loading buffer.
Immunohistochemistry for GBM and Control Tissues
A combined total of 17 GBMs and control brain tissues were obtained from the Markey Cancer Center Biospecimen and Tissue Procurement Shared Resource Facility (BSTP SRF). Formaldahyde-fixed paraffin embedded 5 mm sections were deparaffinized in xylene and rehydrated stepwise using graded ethanol and finally water. Dako antigen retrieval buffer was used with a Biocare Medical decloaking chamber for antigen retrieval following the manufacturer's protocol. Dako peroxidase blocking reagent was used to inhibit endogenous peroxidase activity. Sections were incubated with primary antibody for 1 h at room temperature: APE1, Parkin. Next, sections were incubated with polymer linked secondary antibody, either mouse (Dako K4007) or rabbit (Dako K4003) for 30 min at room temperature followed by development with diaminobenzodine. Following washing, slides were counterstained with Meyer's hematoxylin and allowed to blue in ammonia water before dehydration in graded ethanol. Slides were incubated in xylene before affixing coverslip.
High-resolution digital image slides of GBM and control brain tissue were obtained by scanning with the Aperio ScanScope (Leica, Buffalo Grove) at 20Â magnification. Aperio ImageScope software V 11.2.0.780 and the software's algorithms for Positive Pixel Count V9 and Nuclear V9 were used to analyze these images for % total intensities for APE1 and Parkin in tissue and nuclear localization, respectively.
Chemicals and Other Reagents
CCCP and MG132 were purchased from Sigma. Antibodies used in this study are those for APE1 (Santa Cruz Biotechnology Inc., Dallas, TX, sc-55498), PINK1 (Novus BC100-494 and Protein Tech 23274-1-AP), Parkin (Santa Cruz, sc-32282), b-tubulin (Santa Cruz, sc58884), GAPDH (Invitrogen, AM4300), p53 (Santa Cruz, sc-126). Pre-stained protein molecular weight marker was purchased from New England Biolab, Ipswich, MA (P7709).
RESULTS
Direct Involvement of Parkin in APE1 Ubiquitination
To test whether APE1 is ubiquitinated by Parkin, protein extracts from A549 expressing histidine hexamer-tagged ubiquitin (His-Ub), APE1, Parkin, and PINK1 were subjected to enrichment of His-Ub through nickel resin purification [21] . Monoubiquitinated as well as polyubiquitinated APE1 were detected in the His-Ub enriched fraction when Parkin was expressed ( Figure 1A p53 is a well known target of ubiquitination by other E3 ubiquitin ligases [52] [53] [54] . We tested whether p53 was also efficiently ubiquitinated by Parkin. However, the stability of p53 was unaffected by Parkin and PINK1 ( Figure 1C) . Similarly, proliferating cell nuclear antigen (PCNA), highly susceptible to mono-and poly-ubiquitination [54] , was not modified by Parkin ( Figure 1C ). The unaltered stabilities of p53 and PCNA as well as b-tubulin and b-actin indicated a high specificity of the reaction of Parkin on APE1. Incubating cells with a 26S proteasome inhibitor MG132 restored the APE1 level ( Figure 1D , lane 4 vs. 3).
The Parkin polypeptide contains two RING domains ( Figure S2 ). R275W and C431F missense mutations, which are located in the first and second RING domains in Parkin respectively ( Figure S2 ), abrogate its E3 ligase activity and cause early onset PD [39, 55] . These Parkin mutants failed to degrade APE1 ( Figure 1D lanes 5 and 9; Table 1 ). PINK1 carrying G309D missense mutation is defective in its kinase activity ( Figure S2 ), and incapable of activating Parkin [47, 56, 57] . The G309D PINK1 did not activate APE1 degradation (Figure 1D lane 6 ; Table 1 ). These results suggested that the ligase activity of Parkin was required for APE1 degradation, for which the kinase activity of PINK1 was also critical.
Interaction of APE1 With Parkin
Sarraf et al. recently identified proteins interacting with Parkin and their possible ubiquitination sites, and APE1 was found to be a protein interacting with Parkin through its N-terminal segment, that is, 20-30th amino acids from N-terminus [45] . To probe the importance of the N-terminal region of APE1 for the stability, MEF la cells were transiently transfected with N-terminally truncated APE1, ND20 and ND41 (N-terminal 20 and 41 amino acids deletions), along with Parkin and PINK1. While ND20 APE1 was efficiently degraded by Parkin ( Figure 1E and Table 1 ), ND41 APE1 was significantly more resistant to Parkin dependent degradation compared to those of the fulllength and ND20 APE1 ( Figure 1F and Table 1 ). It is likely that APE1 is mainly ubiquitinated at the amino acid residues 20-41 which contains two Lys clusters (24K-25K-27K and 31K-32K-35K), which is consistent with the previous studies showing that the N-terminal residues contained major ubiquitin acceptor Lys residues catalyzed by MDM2 and UBR3 [21, 24] .
In the normal condition, APE1 in MEF la was localized predominantly in the nuclei (Figure 2A,  control) . When the cells were treated with MG132, cytoplasmic APE1 was visibly increased 3 h after the treatment, and became indistinguishable from the nuclear APE1 after overnight incubation of the cells with MG132 (Figure 2A) . The major fraction of Parkin is present in the cytoplasm [40] . The possibility of cytosolic co-localization of APE1 with Parkin was elucidated, using YFP-Parkin and APE1. After MG132 treatment, APE1 was found to be co-localized with YFP-Parkin in the cytoplasm (Figures 2B and S3) . The cytoplasmic co-localization of APE1 and YFP-Parkin suggested that the physical interaction occurred in the cytoplasm. This possibility was examined with proximity ligation assay (PLA) [58] . Antibodies specific to APE1 and Parkin were used to label the two proteins and signals were detected when the two proteins were in the proximate location to each other ( Figure 2C ). The PLA signal was detected when APE1 and Parkin were co-expressed. Importantly, the PLA was observed mainly in the cytoplasm but not in the nuclei or inside of mitochondria. The absence of Parkin-APE1 interaction in the nuclei is consistent with the cytosolic localization of Parkin in previous studies [59] [60] [61] . To test whether APE1 directly interacts with Parkin without involvement of other cellular factors such as ubiquitin or PINK1, recombinant Parkin was expressed with APE1 or with FLAG-APE1 simultaneously in E. coli, and performed FLAG-immunoprecipitation to detect Parkin in the FLAG-APE1 enriched fraction. Parkin was specifically detected in the FLAG-APE1 containing fraction ( Figure 2D ). The result indicated that APE1 directly interacts with Parkin. Co-immunoprecipitation of Parkin by ND41 APE1-FLAG was significantly decreased ( Figure S4 ) compared to that by full-length APE1, indicating that the N-terminal segment is pivotal for the interaction. However, it should be noted that Parkin signal was not completely disappeared in the ND41-FLAG IP fraction, and we could not exclude the possibility that the downstream APE1 polypeptide is also involved in the interaction of APE1 with Parkin.
Ubiquitination and Degradation of Endogenous APE1 by Parkin and PINK1
To examine the effect of Parkin expression on endogenous APE1, a lung adenocarcinoma cell line A549 was transiently co-transfected with Parkin and its cofactors [39, [62] [63] [64] [65] , namely, Uba1 (E1 ligase), UbcH7 (Parkin-specific E2 ligase), and PINK1 ( Figure 3A) . The level of endogenous APE1 decreased in a does-dependent manner ( Figure 3B ). Densitometry of the immunoblot revealed that the level of the endogenous APE1 was down to 60% of the control cells transfected with the vector plasmid DNA alone.
Levels of the endogenous p53 and PCNA as well as housekeeping proteins b-tubulin and GAPDH were unaltered by the expression of Parkin and its cofactors ( Figure 3B ). These results indicated a high specificity of the reaction of Parkin on APE1, consistent with the results with the ectopically expressed proteins ( Figure 1C ). Total protein extracts from A549 were analyzed for ubiquitination of endogenous APE1. A specific band appeared at the position for monoubiquitinated APE1 after cells were transiently transfected with Parkin ( Figure 3C ). Therefore, endogenous APE1 was ubiquitinated and degraded by Parkin.
Inducible expression of Parkin and PINK1 without transient transfection would provide a more refined experimental condition. To achieve this, a derivative of HEK 293 cell line 293-PaPi was used. The 293-PaPi is a stable transfectant of HEK293, and enables simultaneous induction of Parkin and PINK1 by doxycycline from a bidirectional promoter [48] (Figure S1 ). Induction of Parkin and PINK1 ( Figure 4A ) did not alter APE1 nor b-tubulin while Mfn2 decreased clearly ( Figure 4B ). Because Parkin's E3 ligase function is active at mitochondria, the 293-PaPi cells were treated with H 2 O 2 to increase APE1 in mitochondria [66] . Treatment of the cells with H 2 O 2 decreased APE1 to approximately 70% of the control while the amount of b-tubulin was still unchanged ( Figure 4B ). Although the change of APE1 level by H 2 O 2 in the doxtreated 293-PaPi was statistically significant, dox or H 2 O 2 alone did not show significant difference from the untreated control cells ( Figure 4B ). These results indicated that degradation of APE1 by Parkin was limited compared to the transiently expressed APE1, suggesting that a large portion of APE1 is not in contact with the Parkin and PINK1 without induction of stresses such as oxidative stress.
A human neuroblastoma cell line SH-SY5Y has been used for mitophagy studies because of a relatively high level of endogenous Parkin in the cells. SH-SY5Y cells were incubated with CCCP and the APE1 stability was examined. CCCP is a proton ionophore uncoupling oxidative phosphorylation in mitochondria [67] and stimulates mitophagy via Parkin-driven degradation of mitochondrial proteins 24 h after CCCP treatment [40] . Mitofusin 2 (Mfn2), a mitochondria fusion protein and a known Parkin substrate, was decreased after the CCCP treatment ( Figure 4C ). The CCCP treatment also decreased the Parkin level, consistent with previous observations that Parkin polyubiquitinates itself for degradation as an auto-feedback regulation [68, 69] . Under this condition, moderate decrease of APE1 was observed whereas the level of b-tubulin was unchanged. After normalization with b-tubulin, it was calculated, with statistical significance, that APE1 decreased to 80% of that of untreated cells ( Figure 4C ). The differentiation status of the SH-SY5Y [70] cells did not affect the Parkin activity, as cells that were differentiated with retinoic acid also showed a similar level of decrease of endogenous APE1 with CCCP ( Figure 4C ). PINK1 downregulation by RNA interference resulted in the stabilization of APE1 ( Figure 4D ). These results suggested that Parkin and PINK1 played a role in regulating APE1 levels in the cells.
Loss of Parkin Is Associated With Elevated APE1 Levels in GBM
Parkin deficiency has been associated with GBM [41, 42] . To elucidate the correlation between Parkin and APE1 in brain tumors, expression levels of Parkin and APE1 in both GBM and non-neoplastic brain tissues were examined. Qualities of the monoclonal antibodies for Parkin and APE1 were confirmed in Western blot to detect the corresponding proteins specifically ( Figure 5A ). Interestingly, the GBM tissues showed increased APE1 levels while decreasing the Parkin levels ( Figure 5A ). Parkin and APE1 levels were examined in detail by immunohistochemistry ( Figure 5B ). Parkin levels in the non-neoplastic brain tissues were higher than those of GBM tissues ( Figure 5C , P ¼ 0.0009), while APE1 signals were higher in GBM tissues than the non-neoplastic tissues (P ¼ 0.0025). Parkin/APE1 ratios were calculated, and were significantly lower in the GBM tissues than in the non-neoplastic brain tissues ( Figure 5C , P ¼ 0.0013). Notably, the variance of Parkin/APE1 ratios were significantly lower than that of either APE1 and Parkin levels, implying that the loss of Parkin and the gain of APE1 expression during the tumorigenesis are associated with each other. Ã Relative APE1 intensities (%) in MEF la with the wild-type or mutant Parkin and PINK1 expressions were calculated by comparing with those without Parkin nor PINK1. a APE1 amounts were normalized by b-tubulin, and compared with that without Parkin and PINK1. Values based on more than three independent experiments. b P-values by Student's t-test. Each value (more than three experiments) calculated with the result of the first row (with wt-APE1, wt-Parkin, and wt-PINK1).
DISCUSSION
APE1 is primarily known for repair of oxidized and alkylated DNA damage, but also is an important gene expression regulator that activates transcription factors such as AP-1 and NFkB [71] . Both APE1 functions are pro-proliferation and advantageous to cell survival, which explains elevated APE1 expression in tumor tissues. Indeed, tumor cells with high APE1 levels acquire drug and radiation resistance [8] [9] [10] [11] [12] . Therefore, identifying factors that control APE1 levels should provide information relevant to the cancer therapeutics, particularly those causing cytotoxicity via DNA damage generation.
We speculated a possible role of Parkin for controlling intracellular levels of APE1, because (i) backup E3 coli BLR were subjected to immunoprecipitation using FLAG antibody, and the total and eluted fractions were analyzed in immunoblot using APE1 and Parkin antibodies.
ligase activity was detected in cells defective in MDM2 [20] ; (ii) Parkin is induced by p53 [43, 44] ; and (iii) a proteomics study detected APE1 as a possible substrate of Parkin [45] . The present results show that Parkin is a quite efficient and highly specific E3 ligase to ubiquitinate APE1. The examination of mutant Parkin and PINK1 supports that the ubiquitination reaction is dependent on the E3 ligase activity of Parkin and the kinase activity of PINK1. Evidence for the direct interaction of APE1 with Parkin was obtained with co-immunoprecipitation of APE1 and Parkin and by proximity ligation assay. Based on these results, we conclude that Parkin directly ubiquitinates APE1. While monoubiquitinated APE1 was readily detected by MDM2 and UBR3 [21, 24] , detection of monoubiquitinated APE1 catalyzed by Parkin and PINK1 was relatively difficult. This observation implies that monoubiquitinated APE1 immediately undergoes polyubiquitination process by Parkin, and APE1 is efficiently degraded after the reaction by Parkin. Inhibiting the 26S proteasome by MG132 resulted in increase of monoubiquitinated APE1 in a manner dependent on Parkin and PINK1. Thus, Parkin with its cofactors Uba1, UbcH7, and PINK1 ubiquitinates directly, and degrades APE1 through 26S proteasome more efficiently than those processed by MDM2 and UBR3. Although ND20 APE1 (N-terminal 20 a.a. truncation) was degraded by Parkin as effectively as the fulllength APE1, the stability of ND41 APE1 in the presence of Parkin and PINK1 was significantly increased. The results indicated that the N-terminal polypeptide between 20 and 40 amino residues in APE1 is important for the Parkin-dependent ubiquitination.
The N-terminal 60 amino acid segment in APE1 is not defined well functionally and structurally. This domain is unique in the mammalian AP endonuclease [72] , and is dispensable for the AP-endonuclease activity [73] , and thus it has been speculated that the N-terminal domain has an uncharacterized function unique to mammalian cells. In this context, it is interesting that the segment is rich in Lys, the major acceptor for acetylation and ubiquitination. The Nterminal segment between 20 and 41 amino acid residues contains six Lys residues, namely, 24K, 25K, 27K, 31K, 32K, and 35K. Acetylation of APE1 at these Lys residues were reported [7, 14, 18, 74] . These N-terminal Lys residues were also the main ubiquitin acceptors for MDM2 and UBR3 E3 ligases [21, 24] . Based on a recent quantitative proteomics study, the APE1 segment 18-RTEPEAKKSKTAA-30, containing Lys 24, 25, and 27, was identified to be a possible target of ubiquitination catalyzed by Parkin [45] . Therefore, Lys residues in the N-terminus may be essential for the post-translational modifications that modulates APE1's gene regulatory function [7] and for altering its stability by polyubiquitination.
Although activating Parkin resulted in decrease of endogenous APE1 in three cell lines, SH-SY5Y, A549, and 293-PaPi, it should be noted that Parkin was active on endogenous APE1 only when stressful conditions (CCCP and H 2 O 2 ) were invoked. We speculate that the modest effect of Parkin on endogenous APE1 is due to the fact that the majority of endogenous APE1 is compartmentalized in the nuclei, which may prevent Parkin from reacting on APE1. Stresses induced in the cells activated Parkin system (CCCP in SH-SY5Y) or facilitated mitochondrial localization of APE1 from nuclei (H 2 O 2 in 293) [66] . Although endogenous APE1 significantly decreased in A549 without any treatments, transient transfection is known to induce stress responses [75, 76] . Thus, APE1 ubiquitination by Parkin is unique in that the main site of the reaction is the cytoplasm, which is supported by the proximity ligation assay. In contrast, APE1 ubiquitination by MDM2 and UBR3 occurred mainly in the nuclei [20, 24] . It should be noted that APE1 was copurified with mitochondria, but majority of this APE1 fraction was found to be on the surface of mitochondria [77] , which is the major platform for the Parkin driven protein degradation. However, it is highly plausible in the event of mitophagy, APE1 in the mitochondria becomes the target of Parkin as well.
Although APE1 has been studied for its activities in the nuclei, there is an increasing interest in APE1's presence in the cytoplasm and its cancer-promoting effect [78] [79] [80] . Kakolyris et al. found that APE1 was present in the cytoplasm of the normal human tissues [81] . More recently, malignant cancer cells in the lung exhibited cytoplasmic APE1 at unusually high levels, and was linked to a poor prognosis of cancer treatment [79] . Vascott et al. found that treatment of cells with an APE1 inhibitor E3330 caused cytoplasmic translocation of APE1 [82] . Frossi also found that H 2 O 2 induced translocation of APE1 into mitochondria [66] . These studies suggest a cellular mechanism to export APE1 from nuclei. Based on these previous studies and present results, it is postulated that APE1 ubiquitination by Parkin is active in the cytoplasm, in which damaged APE1 proteins are ubiquitinated and degraded by Parkin to protect cells from undergoing malignant transformation. Meanwhile, undamaged, properly folded APE1 in the nucleus may be protected from this salvage system by the compartmentalization.
Originally identified as a gene of which deficiency is responsible for PD, Parkin was recently reported as a tumor suppressor gene of which loss of heterozygosity was frequently found in GBM [41] . Analysis of Parkin and APE1 expressions in normal and GBM specimens revealed that Parkin/APE1 ratios (expression of Parkin relative to that of APE1) in the GBM tissues were uniformly low, while those in the non-neoplastic brain tissues showed much higher values and larger variance than those in GBM. This observation implies a correlation between the loss of Parkin and the high expression of APE1 in the brain tumor tissues. It is possible that a lack of Parkin activity either by loss of heterozygosity or by p53 mutation may lead to deficiency in regular APE1 degradation, and may accumulate in the cytoplasm as well as in the nuclei. However, the results do not determine whether Parkin deficiency is the direct cause of high APE1 activities in GBM, or vice versa. More recently, Hu et al. reported that melanoma specific inactivation of the Parkin gene [83] . According to the study, melanoma specific Parkin alterations were observed at significantly high odds ratios over healthy control tissues. The alterations included copy number variations, splicing mutations, and putatively inactivating mutations including N273S, R275W, and P437L which are adjacent to the missense mutations that cause early onset Parkinson's disease (R275W and C431F). Further studies are necessary to investigate whether Parkin is crucial for the tight regulation of the intracellular level and subcellular distribution of APE1 to prevent cells from becoming malignant tumors.
